Details for Patent: 9,308,204

Which drugs does patent 9,308,204 protect, and when does it expire?

Patent 9,308,204 protects SEGLUROMET and STEGLUJAN and is included in two NDAs.

This patent has twenty-six patent family members in twenty-three countries.

Summary for Patent: 9,308,204

Title:	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Abstract:	Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001##
Inventor(s):	Mascitti; Vincent (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/535,630
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,308,204

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-002	Dec 19, 2017		RX	Yes	No			Y
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-001	Dec 19, 2017		RX	Yes	No			Y
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-004	Dec 19, 2017		RX	Yes	Yes			Y

International Family Members for US Patent 9,308,204

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3099
Australia	2010310956
Canada	2777857